Loading...
XNAS
SNWV
Market cap280mUSD
Dec 05, Last price  
32.70USD
1D
-3.55%
1Q
-13.69%
Jan 2017
18,593.54%
IPO
522.76%
Name

SANUWAVE Health

Chart & Performance

D1W1MN
XNAS:SNWV chart
P/E
P/S
8.59
EPS
Div Yield, %
Shrs. gr., 5y
-53.40%
Rev. gr., 5y
99.65%
Revenues
33m
+59.99%
000660,725728,446802,572769,217800,029847,367965,5011,376,063738,5271,850,0601,028,7304,057,47113,010,00016,742,00020,398,00032,634,000
Net income
-31m
L+21.56%
21,987-35,692-26,550-6,153,040-14,922,441-10,238,797-6,401,494-11,299,721-5,974,080-4,810,285-6,439,040-5,537,936-11,631,394-12,266,020-34,078,064-27,259,000-10,293,000-25,807,000-31,372,000
CFO
2m
P
-4,072-22,072-41,923-6,271,932-5,867,276-8,831,699-4,290,121-3,924,204-6,678,369-3,473,456-3,199,453-1,528,971-3,621,172-6,410,758-12,718,292-6,409,000-17,169,000-4,538,0002,455,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
IPO date
Nov 07, 2008
Employees
38
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT